Osteomyelitis
Drug research and approvals for osteomyelitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 28 studies of osteomyelitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 28
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting now
Newest start dates first, of 28 recruiting on ClinicalTrials.gov ↗- Reliability and Validation of the WB-MRI Radiological Score in CRMONCT07483853 · Not reported · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Jan 1, 2027
- Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of…NCT07435051 · Phase 3 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Oct 26, 2026
- Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.NCT07270380 · Not applicable · Biocomposites Ltd · starts Oct 20, 2026
- Continuous Antibiotic Infusion In ChildrenNCT07575009 · Phase 3 · Tampere University Hospital · starts Apr 21, 2026
- Comparison of Oral Antibiotics For Bone Infections of the Leg and FootNCT07266753 · Phase 4 · Michael Garron Hospital · starts Feb 26, 2026
- New Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot…NCT07391995 · Not reported · Centre Hospitalier Universitaire de Nīmes · starts Feb 12, 2026
- The ACHILLS Trial; Application of Cerament in Heel Infection for Lower Limb SalvageNCT07057817 · Not applicable · Royal College of Surgeons, Ireland · starts Jan 1, 2026
- A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis…NCT06283979 · Phase 2 · Biocomposites Ltd · starts Jun 15, 2025
- CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage ProcedureNCT06555848 · Not reported · BONESUPPORT AB · starts Jun 2, 2025
- Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA InfectionsNCT06982105 · Phase 4 · Indiana University · starts May 20, 2025
Drug pipeline
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indicationsApproved 5
- Clindamycin phosphateBacterial 70S ribosome inhibitor
- ErtapenemBacterial penicillin-binding protein inhibitor
- LinezolidBacterial 70S ribosome inhibitor
- SulesomabDiagnostic agent
- BesilesomabDiagnostic agent
Phase 3 7
- VancomycinPeptidoglycan inhibitor
- NafcillinPenicillin-binding protein inhibitor
- OxacillinPenicillin-binding protein inhibitor
- DalbavancinPeptidoglycan inhibitor
- DaptomycinCell membrane inhibitor
- TigecyclineBacterial 70S ribosome inhibitor
- CefazolinBacterial penicillin-binding protein inhibitor
Phase 2 2
- TeicoplaninPeptidoglycan disrupting agent
- FloxacillinBacterial penicillin-binding protein inhibitor
Phase 1 or earlier 12 of 115
- AmikacinBacterial 70S ribosome inhibitor
- BacitracinC55-isoprenyl pyrophosphate inhibitor
- CefoxitinBacterial penicillin-binding protein inhibitor
- CeftazidimeBacterial penicillin-binding protein inhibitor
- Chloramphenicol succinic acidBacterial 70S ribosome inhibitor
- CiprofloxacinBacterial DNA gyrase inhibitor
- Clindamycin palmitateBacterial 70S ribosome inhibitor
- Doxycycline anhydrousMatrix metalloproteinase 7 inhibitor
- GentamicinBacterial 70S ribosome inhibitor
- IsoniazidEnoyl-[acyl-carrier-protein] reductase inhibitor
- Lincomycin70S ribosome inhibitor
- MetronidazoleDNA inhibitor
How its trials ended
109 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 32% met their primary endpoint, 5% missed it and 63% stopped early.
- Ongoing3835%
- Completed, result not reported3633%
- Status unknown1615%
- Met its primary endpoint66%
- Stopped: other or unclear55%
- Stopped: enrollment or feasibility33%
- Stopped: sponsor or business decision22%
- Missed its primary endpoint11%
- Stopped: lack of efficacy11%
- Stopped: funding11%
FDA orphan designations
Approved first, then open designations, newest first| Mar 30, 2015 | DalbavancinTreatment of acute osteomyelitis in children (0 through 16 years of age) | Durata Therapeutics International B.V. | Designated |
| Jan 31, 1991 | Gentamicin impregnated PMMA beads on surgical wireTreatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin. | Lipha Pharmaceuticals, Inc. | Designated |
Medicines authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jan 11, 2010 | ScintimunBesilesomab | Telix Innovations | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA